Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

25.73 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
Via Benzinga
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Wellness In Your Personal Life Unleashes Productivity At Work
Our world is obsessed with individual productivity. 
Via Investor's Business Daily
Moderna Unusual Options Activity
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Via Benzinga
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
Via Benzinga
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action
From Robbins LLP
Via GlobeNewswire
This Moderna Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185. 
Via Benzinga
INVESTOR ALERT:   Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
Exposures COVID-19
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
8 large-cap stocks were the worst performers last week: TBN, GFI, SNOW, NTES, BEN, JD, PDD, MRNA. Are they in your portfolio? 
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Kellanova and Fortinet are leading the S&P 500's August performance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
Moderna secures European Commission approval for its mRNA RSV vaccine, mRESVIA, to protect adults 60+ from RSV-related respiratory disease. The approval follows positive EMA CHMP opinion, based on... 
Via Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Via ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Nasdaq 100 Slumps 1.6% As Traders Turn Cautious Ahead Of Powell's Jackson Hole Address
The Nasdaq 100 fell 1.6% on Thursday as investors awaited Fed Chair Powell's Jackson Hole speech. Private sector data and tech stock declines added to bearish sentiment. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks Move Lower As Rate Cut Enthusiasm Fades
The enthusiasm that followed the release of the Federal Reserve's meeting minutes is already fading. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.